{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:20:25Z","timestamp":1790680825804,"version":"4.1.0"},"reference-count":180,"publisher":"Elsevier","isbn-type":[{"value":"9780323899413","type":"print"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007241","name":"Universit\u00e9 Paris-Saclay","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["UMR 1287"],"award-info":[{"award-number":["UMR 1287"]}],"id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/bs.ircmb.2021.02.009","type":"book-chapter","created":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T08:19:03Z","timestamp":1617956343000},"page":"125-185","source":"Crossref","is-referenced-by-count":10,"title":["Lessons from mouse models of MPN"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.ircmb.2021.02.009_bb0010","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/leu.2011.82","article-title":"DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms","volume":"25","author":"Abdel-Wahab","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0015","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1084\/jem.20131141","article-title":"Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo","volume":"210","author":"Abdel-Wahab","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0020","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood-2009-04-215848","article-title":"Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease","volume":"115","author":"Akada","year":"2010","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0025","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1038\/leu.2014.52","article-title":"Loss of wild-type Jak2 allele enhances myeloid cell expansion and accelerates myelofibrosis in Jak2V617F knock-in mice","volume":"28","author":"Akada","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0030","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nature13383","article-title":"Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms","volume":"512","author":"Arranz","year":"2014","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0035","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s41375-019-0638-y","article-title":"Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations","volume":"34","author":"Austin","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0040","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1038\/leu.2016.47","article-title":"Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin","volume":"30","author":"Balligand","year":"2016","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/bs.ircmb.2021.02.009_bb0045","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41375-019-0538-1","article-title":"Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr exon 9 in cardiac development","volume":"34","author":"Balligand","year":"2020","journal-title":"Leukemia"},{"issue":"Suppl. 1","key":"10.1016\/bs.ircmb.2021.02.009_bb0050","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/S0049-3848(16)30102-5","article-title":"Molecular biomarkers of thrombosis in myeloproliferative neoplasms","volume":"140","author":"Barbui","year":"2016","journal-title":"Thromb. Res."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0055","first-page":"3630","article-title":"Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian cooperative study group on myeloid with myeloid metaplasia","volume":"91","author":"Barosi","year":"1998","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0060","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s11899-013-0182-1","article-title":"Preclinical models for drug selection in myeloproliferative neoplasms","volume":"8","author":"Bartalucci","year":"2013","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0065","doi-asserted-by":"crossref","first-page":"100710","DOI":"10.1016\/j.blre.2020.100710","article-title":"Germline genetic factors in the pathogenesis of myeloproliferative neoplasms","volume":"42","author":"Bellann\u00e9-Chantelot","year":"2020","journal-title":"Blood Rev."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0070","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1038\/s41467-020-18691-3","article-title":"Calreticulin del52 and ins5 knock-in mice recapitulate different myeloproliferative phenotypes observed in patients with MPN","volume":"11","author":"Benlabiod","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0075","doi-asserted-by":"crossref","first-page":"11156","DOI":"10.1158\/0008-5472.CAN-06-2210","article-title":"Characterization of murine JAK2V617F-positive myeloproliferative disease","volume":"66","author":"Bumm","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0080","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/ng.2413","article-title":"Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis","volume":"44","author":"Busque","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0085","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/leu.2014.270","article-title":"Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution","volume":"29","author":"Cabagnols","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0090","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nbt0697-570","article-title":"Augmentation of blood platelet levels by intratracheal administration of an adenovirus vector encoding human thrombopoietin cDNA","volume":"15","author":"Cannizzo","year":"1997","journal-title":"Nat. Biotechnol."},{"issue":"12","key":"10.1016\/bs.ircmb.2021.02.009_bb0095","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1111\/jth.15095","article-title":"Endothelial JAK2V617F mutation leads to thrombosis, vasculopathy, and cardiomyopathy in a murine model of myeloproliferative neoplasm","volume":"18","author":"Castiglione","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0100","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1182\/blood-2002-04-1133","article-title":"Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice","volume":"100","author":"Chagraoui","year":"2002","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0105","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood-2002-09-2839","article-title":"Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO","volume":"101","author":"Chagraoui","year":"2003","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0110","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/ng.1009","article-title":"Dnmt3a is essential for hematopoietic stem cell differentiation","volume":"44","author":"Challen","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221635","article-title":"A conditional inducible JAK2V617F transgenic mouse model reveals myeloproliferative disease that is reversible upon switching off transgene expression","volume":"14","author":"Chapeau","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0120","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ccr.2010.10.013","article-title":"Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling","volume":"18","author":"Chen","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0125","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1182\/blood-2014-04-567024","article-title":"Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms","volume":"125","author":"Chen","year":"2015","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0130","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1182\/bloodadvances.2019000967","article-title":"N-acetylcysteine inhibits thrombosis in a murine model of myeloproliferative neoplasm","volume":"4","author":"Craver","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0135","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1074-7613(04)00022-6","article-title":"SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis","volume":"20","author":"Croker","year":"2004","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/bs.ircmb.2021.02.009_bb0140","doi-asserted-by":"crossref","first-page":"e20201268","DOI":"10.1084\/jem.20201268","article-title":"JAK2V617F myeloproliferative neoplasm eradication by a novel interferon\/arsenic therapy involves PML","volume":"218","author":"Dagher","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0145","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1111\/jcmm.12608","article-title":"JAK2 inhibition has different therapeutic effects according to myeloproliferative neoplasm development in mice","volume":"19","author":"Debeurme","year":"2015","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0150","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/ncb3530","article-title":"Leptin-receptor-expressing bone marrow stromal cells are myofibroblasts in primary myelofibrosis","volume":"19","author":"Decker","year":"2017","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0155","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2006-03-007146","article-title":"Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis","volume":"109","author":"Delhommeau","year":"2007","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0160","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0165","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/nature20131","article-title":"Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment","volume":"539","author":"Dong","year":"2016","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0170","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/jamacardio.2018.3965","article-title":"Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure","volume":"4","author":"Dorsheimer","year":"2019","journal-title":"JAMA Cardiol."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0175","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1182\/blood-2013-07-514208","article-title":"Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs","volume":"123","author":"Duek","year":"2014","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0180","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1158\/2159-8290.CD-15-1434","article-title":"Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation","volume":"6","author":"Elf","year":"2016","journal-title":"Cancer Discov."},{"issue":"31","key":"10.1016\/bs.ircmb.2021.02.009_bb0185","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1038\/s41388-020-1368-3","article-title":"Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms","volume":"39","author":"El-Khoury","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0190","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/j.ajpath.2017.04.006","article-title":"Endothelial-to-mesenchymal transition in bone marrow and spleen of primary myelofibrosis","volume":"187","author":"Erba","year":"2017","journal-title":"Am. J. Pathol."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0195","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders","volume":"42","author":"Ernst","year":"2010","journal-title":"Nat. Genet."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0200","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1073\/pnas.1312148111","article-title":"JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms","volume":"111","author":"Etheridge","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6487","key":"10.1016\/bs.ircmb.2021.02.009_bb0205","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaw5473","article-title":"Metabolic reprogramming and cancer progression","volume":"368","author":"Faubert","year":"2020","journal-title":"Science"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0210","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2009-07-230698","article-title":"Loss-of-function additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia","volume":"115","author":"Fisher","year":"2010","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0215","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2011-04-348144","article-title":"TNF\u03b1 facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms","volume":"118","author":"Fleischman","year":"2011","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0220","first-page":"1587","article-title":"Adenovirus long-term expression of thrombopoietin in vivo: a new model for myeloproliferative syndrome and osteomyelofibrosis","volume":"128","author":"Frey","year":"1998","journal-title":"Schweiz. Med. Wochenschr."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0225","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1126\/science.aag1381","article-title":"Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice","volume":"355","author":"Fuster","year":"2017","journal-title":"Science"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0230","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.exphem.2006.08.016","article-title":"Adenoviral-mediated TGF-beta1 inhibition in a mouse model of myelofibrosis inhibit bone marrow fibrosis development","volume":"35","author":"Gastinne","year":"2007","journal-title":"Exp. Hematol."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0235","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1182\/blood-2004-08-3037","article-title":"In vivo fate-tracing studies using the Scl stem cell enhancer: embryonic hematopoietic stem cells significantly contribute to adult hematopoiesis","volume":"105","author":"G\u00f6thert","year":"2005","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0240","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.leukres.2017.01.006","article-title":"Pegylated interferon alpha\u20142a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial","volume":"54","author":"Gowin","year":"2017","journal-title":"Leuk. Res."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0245","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","article-title":"Inflammation and cancer: triggers, mechanisms, and consequences","volume":"51","author":"Greten","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0250","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1182\/blood-2014-08-594572","article-title":"Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPN","volume":"125","author":"Grisouard","year":"2015","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0255","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood-2015-12-689216","article-title":"JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis","volume":"128","author":"Grisouard","year":"2016","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0260","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0265","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1182\/blood-2014-04-566760","article-title":"Gray platelet syndrome: proinflammatory megakaryocytes and \u03b1-granule loss cause myelofibrosis and confer metastasis resistance in mice","volume":"124","author":"Guerrero","year":"2014","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0270","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1634\/stemcells.2006-0351","article-title":"Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1)","volume":"25","author":"Guglielmelli","year":"2007","journal-title":"Stem Cells"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0275","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/s41375-018-0347-y","article-title":"ASXL1 alteration cooperates with JAK2V617F to accelerate myelofibrosis","volume":"33","author":"Guo","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0280","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3324\/haematol.2018.195321","article-title":"Vascular endothelial cell expression of JAK2V617F is sufficient to promote a pro-thrombotic state due to increased P-selectin expression","volume":"104","author":"Guy","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0285","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1182\/blood-2013-04-498956","article-title":"JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFN\u03b1","volume":"122","author":"Hasan","year":"2013","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0290","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1182\/blood-2013-06-501452","article-title":"JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia","volume":"122","author":"Hobbs","year":"2013","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0295","doi-asserted-by":"crossref","first-page":"18820","DOI":"10.1073\/pnas.1318974110","article-title":"Rescue of a primary myelofibrosis model by retinoid-antagonist therapy","volume":"110","author":"Hong","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0300","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13045-017-0508-x","article-title":"The distinct biological implications of Asxl1 mutation and its roles in leukemogenesis revealed by a knock-in mouse model","volume":"10","author":"Hsu","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0305","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1172\/JCI33010","article-title":"STAT1 promotes megakaryopoiesis downstream of GATA-1 in mice","volume":"117","author":"Huang","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0310","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.1172\/JCI70739","article-title":"Myelodysplastic syndromes are induced by histone methylation\u2013altering ASXL1 mutations","volume":"123","author":"Inoue","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0315","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.exphem.2015.11.011","article-title":"Truncation mutants of ASXL1 observed in myeloid malignancies are expressed at detectable protein levels","volume":"44","author":"Inoue","year":"2016","journal-title":"Exp. Hematol."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0320","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1182\/blood-2018-04-846220","article-title":"Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation","volume":"132","author":"Jacquelin","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/bs.ircmb.2021.02.009_bb0325","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.3390\/cancers12092381","article-title":"Murine models of myelofibrosis","volume":"12","author":"Jacquelin","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0330","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0335","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0340","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.leukres.2004.12.009","article-title":"Transgenic mice overexpressing murine thrombopoietin develop myelofibrosis and osteosclerosis","volume":"29","author":"Kakumitsu","year":"2005","journal-title":"Leuk. Res."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0345","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1182\/blood-2014-04-555508","article-title":"Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator","volume":"125","author":"Kameda","year":"2015","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0350","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001576","article-title":"Self-renewal of single mouse hematopoietic stem cells is reduced by JAK2V617F without compromising progenitor cell expansion","volume":"11","author":"Kent","year":"2013","journal-title":"PLoS Biol."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0355","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0360","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2007-04-085670","article-title":"Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of down syndrome","volume":"111","author":"Kirsammer","year":"2008","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0365","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0370","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nature11303","article-title":"Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy","volume":"489","author":"Koppikar","year":"2012","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0375","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/blood-2018-02-834820","article-title":"The identification of fibrosis-driving myofibroblast precursors reveals new therapeutic avenues in myelofibrosis","volume":"131","author":"Kramann","year":"2018","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0380","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/path.4253","article-title":"Understanding the origin, activation and regulation of matrix-producing myofibroblasts for treatment of fibrotic disease","volume":"231","author":"Kramann","year":"2013","journal-title":"J. Pathol."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0385","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.stem.2014.11.004","article-title":"Perivascular Gli1+ progenitors are key contributors to injury-induced organ fibrosis","volume":"16","author":"Kramann","year":"2015","journal-title":"Cell Stem Cell"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0390","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1182\/blood-2012-03-415646","article-title":"Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model","volume":"121","author":"Kubovcakova","year":"2013","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0395","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2006-02-002030","article-title":"JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis","volume":"108","author":"Lacout","year":"2006","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0400","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1182\/blood-2013-10-530832","article-title":"Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm","volume":"124","author":"Lamrani","year":"2014","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0405","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood-2009-12-259747","article-title":"JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia","volume":"116","author":"Li","year":"2010","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0410","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1182\/blood-2013-06-510222","article-title":"JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease","volume":"123","author":"Li","year":"2014","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0415","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood-2017-09-806356","article-title":"Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage","volume":"131","author":"Li","year":"2018","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0420","doi-asserted-by":"crossref","first-page":"18962","DOI":"10.1073\/pnas.0509714102","article-title":"Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation","volume":"102","author":"Lu","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0425","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1084\/jem.20131371","article-title":"Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F","volume":"211","author":"Lundberg","year":"2014","journal-title":"J. Exp. Med."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0430","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1182\/blood.2019001163","article-title":"Description of a knock-in mouse model of JAK2V617F MPN emerging from a minority of mutated hematopoietic stem cells","volume":"134","author":"Mansier","year":"2019","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0435","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1182\/blood-2005-03-1060","article-title":"Variegation of the phenotype induced by the Gata1low mutation in mice of different genetic backgrounds","volume":"106","author":"Martelli","year":"2005","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0440","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood-2009-12-257063","article-title":"Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice","volume":"116","author":"Marty","year":"2010","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0445","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/leu.2013.102","article-title":"A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression","volume":"27","author":"Marty","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0450","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1182\/blood-2015-11-679571","article-title":"Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis","volume":"127","author":"Marty","year":"2016","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0455","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3109\/10428194.2013.805329","article-title":"Anti-transforming growth factor-\u03b2 therapy in patients with myelofibrosis","volume":"55","author":"Mascarenhas","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0460","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1161\/ATVBAHA.120.314760","article-title":"Platelet dysfunction and thrombosis in JAK2V617F-mutated primary myelofibrotic mice","volume":"40","author":"Matsuura","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0465","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1172\/JCI94516","article-title":"JAK2\/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition","volume":"128","author":"McKenney","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0470","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1083\/jcb.144.5.857","article-title":"Calreticulin is essential for cardiac development","volume":"144","author":"Mesaeli","year":"1999","journal-title":"J. Cell Biol."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0475","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.4049\/jimmunol.172.5.2731","article-title":"Of mice and not men: differences between mouse and human immunology","volume":"172","author":"Mestas","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0480","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/stem.160314","article-title":"The molecular control of hematopoiesis: progress and problems with gene manipulation","volume":"16","author":"Metcalf","year":"1998","journal-title":"Stem Cells"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0485","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ccell.2015.06.006","article-title":"CHZ868, a type II JAK2 inhibitor, reverses type I JAK inhibitor persistence and demonstrates efficacy in myeloproliferative neoplasms","volume":"28","author":"Meyer","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0490","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007286","article-title":"Splenectomy normalizes hematocrit in murine polycythemia vera","volume":"4","author":"Mo","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0495","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2011.06.001","article-title":"Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation","volume":"20","author":"Moran-Crusio","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0500","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1182\/blood-2009-12-255943","article-title":"Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: a study of 172 patients","volume":"115","author":"Morel","year":"2010","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0505","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","article-title":"Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells","volume":"17","author":"Mullally","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0510","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1182\/blood-2012-01-402396","article-title":"Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera","volume":"120","author":"Mullally","year":"2012","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0515","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1182\/blood-2012-05-432989","article-title":"Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-\u03b1 in a murine model of polycythemia vera","volume":"121","author":"Mullally","year":"2013","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0520","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1084\/jem.20171151","article-title":"Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation","volume":"215","author":"Nagase","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0525","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0530","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.3324\/haematol.2015.129510","article-title":"DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype","volume":"100","author":"Nangalia","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0535","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrc3184","article-title":"Cancer stem cells: an evolving concept","volume":"12","author":"Nguyen","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0540","first-page":"54624","article-title":"Transduction-transplantation mouse model of myeloproliferative neoplasm","volume":"118","author":"Nguyen","year":"2016","journal-title":"J. Vis. Exp."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0545","first-page":"96","article-title":"Practical murine hematopathology: a comparative review and implications for research","volume":"65","author":"O'Connell","year":"2015","journal-title":"Comp. Med."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0550","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood.V88.3.778.778","article-title":"In vivo adenovirus vector-mediated transfer of the human thrombopoietin cDNA maintains platelet levels during radiation-and chemotherapy-induced bone marrow suppression","volume":"88","author":"Ohwada","year":"1996","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0555","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0560","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176345","article-title":"Impact of the c-MybE308G mutation on mouse myelopoiesis and dendritic cell development","volume":"12","author":"Papathanasiou","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0565","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1056\/NEJMoa042905","article-title":"Multidetector-row computed tomography in suspected pulmonary embolism","volume":"352","author":"Perrier","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0570","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/leu.2015.277","article-title":"Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms","volume":"30","author":"Pietra","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0575","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0580","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jhep.2018.01.010","article-title":"Endothelial JAK2V617F does not enhance liver lesions in mice with Budd-Chiari syndrome","volume":"68","author":"Poisson","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0585","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1172\/JCI124566","article-title":"Erythrocyte-derived microvesicles induce arterial spasms in JAK2V617F myeloproliferative neoplasm","volume":"130","author":"Poisson","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0590","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Quint\u00e1s-Cardama","year":"2010","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0595","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nrd3264","article-title":"Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond","volume":"10","author":"Quint\u00e1s-Cardama","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0600","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ccr.2011.06.003","article-title":"TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis","volume":"20","author":"Quivoron","year":"2011","journal-title":"Cancer Cell"},{"issue":"Supplement 1","key":"10.1016\/bs.ircmb.2021.02.009_bb0605","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1182\/blood-2019-129800","article-title":"IL-1\u03b2 Secreted from mutant cells carrying JAK2-V617F favors early clonal expansion and promotes MPN disease initiation and progression","volume":"134","author":"Rai","year":"2019","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0610","doi-asserted-by":"crossref","first-page":"E5401","DOI":"10.1073\/pnas.1407792111","article-title":"Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms","volume":"111","author":"Rampal","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0615","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/nrc1235","article-title":"Opinion: comparative biology of mouse versus human cells: modelling human cancer in mice","volume":"3","author":"Rangarajan","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0620","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1182\/blood.2019000162","article-title":"JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms","volume":"134","author":"Rao","year":"2019","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0625","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.semcdb.2008.06.004","article-title":"Ups and downs: the STAT1:STAT3 seesaw of interferon and gp130 receptor signalling","volume":"19","author":"Regis","year":"2008","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0630","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1146\/annurev-immunol-032712-095921","article-title":"Human hemato-lymphoid system mice: current use and future potential for medicine","volume":"31","author":"Rongvaux","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0635","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2012-01-404889","article-title":"Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation","volume":"121","author":"Rosti","year":"2013","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0640","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0645","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.immuni.2005.02.009","article-title":"Stroma-mediated dysregulation of myelopoiesis in mice lacking I kappa B alpha","volume":"22","author":"Rupec","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0650","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/ng.3380","article-title":"Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies","volume":"47","author":"Saliba","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0655","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1182\/blood-2014-07-587238","article-title":"The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm","volume":"124","author":"Sangkhae","year":"2014","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0660","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1161\/CIRCRESAHA.118.313225","article-title":"CRISPR-mediated gene editing to assess the roles of Tet2 and Dnmt3a in clonal hematopoiesis and cardiovascular disease","volume":"123","author":"Sano","year":"2018","journal-title":"Circ. Res."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0665","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/10428194.2013.794269","article-title":"Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation","volume":"55","author":"Santos","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0670","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nature11323","article-title":"IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics","volume":"488","author":"Sasaki","year":"2012","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0675","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1084\/jem.20151121","article-title":"The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition","volume":"213","author":"Sashida","year":"2016","journal-title":"J. Exp. Med."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0680","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.stem.2017.03.008","article-title":"Gli1+ mesenchymal stromal cells are a key driver of bone marrow fibrosis and an important cellular therapeutic target","volume":"20","author":"Schneider","year":"2017","journal-title":"Cell Stem Cell"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0685","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0690","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.leu.2405043","article-title":"Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F","volume":"22","author":"Shide","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0695","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1038\/leu.2012.94","article-title":"TET2 is essential for survival and hematopoietic stem cell homeostasis","volume":"26","author":"Shide","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0700","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/leu.2016.308","article-title":"Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib","volume":"31","author":"Shide","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0705","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41408-019-0202-z","article-title":"Mice with Calr mutations homologous to human CALR mutations only exhibit mild thrombocytosis","volume":"9","author":"Shide","year":"2019","journal-title":"Blood Cancer J."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0710","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nrc3343","article-title":"The role of mutations in epigenetic regulators in myeloid malignancies","volume":"12","author":"Shih","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0715","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20151136","article-title":"Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis","volume":"213","author":"Shimizu","year":"2016","journal-title":"J. Exp. Med."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0720","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1182\/blood-2010-06-287318","article-title":"JAK2 impairs stem cell function?","volume":"116","author":"Skoda","year":"2010","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0725","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1053\/j.seminhematol.2013.03.029","article-title":"Modeling human hematopoietic stem cell biology in the mouse","volume":"50","author":"Sykes","year":"2013","journal-title":"Semin. Hematol."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0730","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1182\/blood-2016-06-722645","article-title":"Somatic JAK2 mutations and their tumor phenotypes","volume":"128","author":"Tefferi","year":"2016","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0735","doi-asserted-by":"crossref","first-page":"E121","DOI":"10.1002\/ajh.23743","article-title":"Type 1 versus type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients","volume":"89","author":"Tefferi","year":"2014","journal-title":"Am. J. Hematol."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0740","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2007-01-069237","article-title":"Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation","volume":"110","author":"Teofili","year":"2007","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0745","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2007-08-107748","article-title":"Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice","volume":"111","author":"Tiedt","year":"2008","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0750","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1182\/blood-2004-07-2826","article-title":"Transgenic expression of BACH1 transcription factor results in megakaryocytic impairment","volume":"105","author":"Toki","year":"2005","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0755","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/s41388-018-0538-z","article-title":"Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice","volume":"38","author":"Toppaldoddi","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0760","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1038\/onc.2016.478","article-title":"Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera","volume":"36","author":"Tsuruta-Kishino","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0765","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1182\/blood-2009-05-223727","article-title":"CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms","volume":"115","author":"Tyner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0770","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1182\/bloodadvances.2017004457","article-title":"Hmga2 collaborates with JAK2V617F in the development of myeloproliferative neoplasms","volume":"1","author":"Ueda","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0775","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1182\/blood.V87.12.5006.bloodjournal87125006","article-title":"Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice","volume":"87","author":"Ulich","year":"1996","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0780","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41375-018-0198-6","article-title":"Modeling ASXL1 mutation revealed impaired hematopoiesis caused by derepression of p16Ink4a through aberrant PRC1-mediated histone modification","volume":"33","author":"Uni","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0785","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2002-06-1913","article-title":"Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice)","volume":"100","author":"Vannucchi","year":"2002","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0790","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0795","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1084\/jem.20160283","article-title":"Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis","volume":"213","author":"Verstovsek","year":"2016","journal-title":"J. Exp. Med."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0800","first-page":"107","article-title":"Fatal polycythemia induced in mice by dysregulated erythropoietin production by hematopoietic cells","volume":"6","author":"Villeval","year":"1992","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0805","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1182\/blood.V90.11.4369","article-title":"High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice","volume":"90","author":"Villeval","year":"1997","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0810","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.cell.2007.05.014","article-title":"A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency","volume":"129","author":"Walkley","year":"2007","journal-title":"Cell"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0815","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1182\/blood-2011-12-397554","article-title":"Essential role for Stat5a\/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice","volume":"119","author":"Walz","year":"2012","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0820","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1182\/blood-2013-05-500272","article-title":"Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0825","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/369571a0","article-title":"cMpl ligand is a humoral regulator of megakaryocytopoiesis","volume":"369","author":"Wendling","year":"1994","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0830","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1182\/blood-2005-12-4824","article-title":"Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model","volume":"107","author":"Wernig","year":"2006","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0835","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccr.2008.02.009","article-title":"Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera","volume":"13","author":"Wernig","year":"2008","journal-title":"Cancer Cell"},{"issue":"436","key":"10.1016\/bs.ircmb.2021.02.009_bb0840","doi-asserted-by":"crossref","first-page":"eaan8292","DOI":"10.1126\/scitranslmed.aan8292","article-title":"Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms","volume":"10","author":"Wolach","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0845","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0850","doi-asserted-by":"crossref","first-page":"5109","DOI":"10.1182\/blood-2007-05-091579","article-title":"Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice","volume":"111","author":"Xing","year":"2008","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0855","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.cell.2011.09.053","article-title":"Nonmyelinating Schwann cells maintain hematopoietic stem cell hibernation in the bone marrow niche","volume":"147","author":"Yamazaki","year":"2011","journal-title":"Cell"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0860","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1182\/blood.V86.11.4025.bloodjournal86114025","article-title":"Chronic exposure to retroviral vector encoded MGDF (mpl-ligand) induces lineage-specific growth and differentiation of megakaryocytes in mice","volume":"86","author":"Yan","year":"1995","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0865","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1182\/blood.V88.2.402.bloodjournal882402","article-title":"A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation","volume":"88","author":"Yan","year":"1996","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0870","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1182\/blood-2011-03-345215","article-title":"Critical requirement for Stat5 in a mouse model of polycythemia vera","volume":"119","author":"Yan","year":"2012","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0875","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1038\/leu.2015.116","article-title":"Deletion of Stat3 enhances myeloid cell expansion and increases the severity of myeloproliferative neoplasms in Jak2V617F knock-in mice","volume":"29","author":"Yan","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0880","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1182\/blood-2015-11-679431","article-title":"Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm","volume":"127","author":"Yang","year":"2016","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0885","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood-2017-06-789669","article-title":"Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies","volume":"131","author":"Yang","year":"2018","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0890","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.90932","article-title":"Efficacy of ALK5 inhibition in myelofibrosis","volume":"2","author":"Yue","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0895","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0000018","article-title":"Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F","volume":"1","author":"Zaleskas","year":"2006","journal-title":"PLoS One"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0900","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/blood.V89.5.1551","article-title":"Transgenic mice overexpressing human c-mpl ligand exhibit chronic thrombocytosis and display enhanced recovery from 5-fluorouracil or antiplatelet serum treatment","volume":"89","author":"Zhou","year":"1997","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.009_bb0905","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1182\/blood-2012-06-439661","article-title":"Characterization of the TGF-\u03b21 signaling abnormalities in the Gata1low mouse model of myelofibrosis","volume":"121","author":"Zingariello","year":"2013","journal-title":"Blood"}],"container-title":["International Review of Cell and Molecular Biology","Cellular and Molecular Aspects of Myeloproliferative Neoplasms \u2013 Part B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644821000149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644821000149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T10:32:21Z","timestamp":1762597941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1937644821000149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9780323899413"],"references-count":180,"URL":"https:\/\/doi.org\/10.1016\/bs.ircmb.2021.02.009","relation":{},"ISSN":["1937-6448"],"issn-type":[{"value":"1937-6448","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}